Details for Patent: 8,201,556
✉ Email this page to a colleague
Which drugs does patent 8,201,556 protect, and when does it expire?
Patent 8,201,556 protects ARNUITY ELLIPTA and INCRUSE ELLIPTA and is included in two NDAs.
This patent has nineteen patent family members in seventeen countries.
Summary for Patent: 8,201,556
| Title: | Medicament dispenser |
| Abstract: | There is provided a sheet driver for use in a medicament dispenser including a medicament carrier having a plurality of pockets for containing medicament wherein said pockets are spaced along the length of and defined between first and second sheets secured to each other and separable by drivable pulling action, the sheet driver comprising a base; ascending from the base, a shaft defining a rotational axis; on the base, a drive surface for receipt of drive to rotate the base about the rotational axis; about the shaft, a torsion spring defining first and second spring legs; mounting about the shaft and the torsion spring for rotation about the rotational axis, a hub defining a hub surface for receipt of a sheet of the medicament carrier. A first leg receiver of the base receives the first spring leg of the torsion spring and a second leg receiver of the hub receives the second spring leg of the torsion spring such that relative rotation of the base and the hub results in tensioning of the torsion spring. |
| Inventor(s): | Jones; Christopher John (Warwick, GB), May; James John (Warwick, GB), Lintell; Daniel Thomas De Sausmarez (Ware, GB), Palmer; Mark Gregory (Ware, GB), Tansley; Robert William (Bidford on Avon, GB) |
| Assignee: | Glaxo Group Limited (Greenford, Middlesex, GB) |
| Application Number: | 11/573,656 |
|
Patent Claim Types: see list of patent claims | Use; Composition; Dosage form; |
Drugs Protected by US Patent 8,201,556
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Patented / Exclusive Use | Submissiondate |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Glaxosmithkline | ARNUITY ELLIPTA | fluticasone furoate | POWDER;INHALATION | 205625-003 | May 17, 2018 | RX | Yes | Yes | ⤷ Try a Trial | ⤷ Try a Trial | Y | ⤷ Try a Trial | ||||
| Glaxosmithkline | ARNUITY ELLIPTA | fluticasone furoate | POWDER;INHALATION | 205625-001 | Aug 20, 2014 | RX | Yes | Yes | ⤷ Try a Trial | ⤷ Try a Trial | Y | ⤷ Try a Trial | ||||
| Glaxosmithkline | ARNUITY ELLIPTA | fluticasone furoate | POWDER;INHALATION | 205625-002 | Aug 20, 2014 | RX | Yes | Yes | ⤷ Try a Trial | ⤷ Try a Trial | Y | ⤷ Try a Trial | ||||
| Glaxo Grp England | INCRUSE ELLIPTA | umeclidinium bromide | POWDER;INHALATION | 205382-001 | Apr 30, 2014 | RX | Yes | Yes | ⤷ Try a Trial | ⤷ Try a Trial | Y | ⤷ Try a Trial | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Patented / Exclusive Use | >Submissiondate |
Foreign Priority and PCT Information for Patent: 8,201,556
| Foriegn Application Priority Data | ||
| Foreign Country | Foreign Patent Number | Foreign Patent Date |
| United Kingdom | 0418278.8 | Aug 16, 2004 |
| PCT Information | |||
| PCT Filed | August 12, 2005 | PCT Application Number: | PCT/EP2005/008842 |
| PCT Publication Date: | February 23, 2006 | PCT Publication Number: | WO2006/018261 |
International Family Members for US Patent 8,201,556
| Country | Patent Number | Estimated Expiration | Supplementary Protection Certificate | SPC Country | SPC Expiration |
|---|---|---|---|---|---|
| Australia | 2005274296 | ⤷ Try a Trial | |||
| Brazil | PI0514346 | ⤷ Try a Trial | |||
| Canada | 2577248 | ⤷ Try a Trial | |||
| China | 100528256 | ⤷ Try a Trial | |||
| >Country | >Patent Number | >Estimated Expiration | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration |
